Rallybio Corporation
RLYB
$14.35
$0.322.28%
NASDAQ
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 4.72% | 0.00% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 4.72% | 0.00% | |||
| Cost of Revenue | -11.78% | 570.39% | |||
| Gross Profit | 12.67% | -868.23% | |||
| SG&A Expenses | -0.50% | -28.63% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -7.05% | -30.50% | |||
| Operating Income | 7.41% | 31.14% | |||
| Income Before Tax | -136.54% | 265.06% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -136.54% | 265.06% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -136.54% | 265.06% | |||
| EBIT | 7.41% | 31.14% | |||
| EBITDA | 6.98% | 31.31% | |||
| EPS Basic | -136.21% | 264.27% | |||
| Normalized Basic EPS | 10.26% | 33.71% | |||
| EPS Diluted | -136.21% | 264.27% | |||
| Normalized Diluted EPS | 10.26% | 33.71% | |||
| Average Basic Shares Outstanding | 0.90% | 0.49% | |||
| Average Diluted Shares Outstanding | 0.90% | 0.49% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||